EQUILLIUM, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
EQUILLIUM, INC. (EQ) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.99% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-25
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.56%.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.99%, a 0.25% increase from fiscal 2024.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.98%, a 1.27% increase from fiscal 2023.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.93%, a 103.63% increase from fiscal 2022.
- EQUILLIUM, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.93%, a 183.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|
| 2025-12-31 | 3.99% 10-K · filed 2026-03-25 | |
| 2024-12-31 | 3.98% 10-K · filed 2026-03-25 | |
| 2023-12-31 | 3.93% 10-K · filed 2025-03-27 | |
| 2022-12-31 | 1.93% 10-K · filed 2024-03-25 | |
| 2021-12-31 | 0.68% 10-K · filed 2023-03-23 | |
| 2020-12-31 | 0.65% 10-K · filed 2022-03-23 | |
| 2019-12-31 | 2.23% 10-K · filed 2021-03-24 | |
| 2019-03-31 | 2.56% 10-Q · filed 2019-05-13 | |
| 2018-12-31 | 2.83% 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |